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For commonly encountered gram-negative bacilli, aMIC of cefepime of 8g/ml or less was defined by the Clinical
and Laboratory Standards Institute as “susceptible” prior to the commercial release of the antibiotic. We assessed
204 episodes of bacteremia caused by gram-negative organisms for which patients received cefepime (typically 1 to
2 g every 12 h) as the primary mode of therapy. The cefepime MIC breakpoint derived by classification and
regression tree (CART) software analysis to delineate the risk of 28-day mortality was 8 g/ml. Patients infected
with gram-negative organisms treated with cefepime at a MIC of >8 g/ml had a mortality rate of 54.8% (17/31
died), compared to 24.1% (35/145 died) for those treated with a cefepime MIC of <8 g/ml. The rate of mortality
for those treated with a cefepime MIC of 8 g/ml was 56.3% (9/16 died), compared to 53.3% (8/15 died) for those
treated with cefepime at a MIC of >8 g/ml. A multivariable analysis including severity of illness indices showed
that treating patients with bacteremia due to gram-negative organisms with a cefepime MIC of >8 g/ml was an
independent predictor of mortality (P < 0.001). There was no significant difference in outcome according to the
dosage regimen utilized. Pharmacodynamic assessments that were presented previously would suggest that
cefepime treatment (particularly a dosage of 1 g every 12 h) has a low probability of target attainment associated
with successful in vivo outcome when the cefepime MIC is >8 g/ml. It would appear reasonable, based on
pharmacodynamic and clinical grounds, to lower the breakpoints for cefepime in countries where the cefepime
dosage of 1 to 2 g every 12 h is the licensed therapy for serious infections, so that organisms with a cefepime MIC
of 8 g/ml are no longer regarded as susceptible to the antibiotic.
Breakpoints for differentiating between organisms that are sus-
ceptible or resistant to antimicrobial agents are determined by
several different organizations. These organizations, including the
U.S. Food and Drug Administration (FDA), the Clinical and
Laboratory Standards Institute (CLSI), the European Committee
on Antimicrobial Susceptibility Testing (EUCAST), and various
national organizations, determine breakpoints for antimicrobial
susceptibility at the time an antibiotic is undergoing approval for
clinical use. Such breakpoints may also be revised when microbi-
ologic, pharmacodynamic, or clinical information suggests a med-
ical necessity to do so. Cefepime breakpoints for gram-negative
bacilli were determined prior to the drug’s commercial release
more than a decade ago. The current breakpoints determined by
the FDA and CLSI for the cefepime MIC against infection by the
Enterobacteriaceae family, Pseudomonas aeruginosa, and Acineto-
bacter spp. are 8 g/ml (susceptible), 16 g/ml (intermediate),
and32 g/ml (resistant). In contrast, EUCAST breakpoints for
cefepime MIC against theEnterobacteriaceae family are1g/ml
(susceptible), 2 to 8 g/ml (intermediate), and 8 g/ml (resis-
tant); and EUCAST breakpoints for cefepime MIC against
Pseudomonas aeruginosa are 8 g/ml (susceptible) and 8
g/ml (resistant). No EUCAST breakpoints exist for cefepime
against Acinetobacter spp.
Given these disparities in breakpoints for such a commonly
used antibiotic as cefepime, we examined the clinical outcomes
of patients with bacteremia caused by gram-negative organisms
(gram-negative bacteremia) treated with cefepime to deter-
mine whether current breakpoints need to be revised or har-
monized.
MATERIALS AND METHODS
Patients. We reviewed our hospital’s clinical microbiology database to identify
patients with gram-negative bacteremia. Next, we identified those patients who
received cefepime as the primary mode of therapy. This mode was defined as
cefepime therapy which was started within 1 calendar day of the date on which
blood cultures were found to be positive. We included both those patients who
received cefepime monotherapy and those who received it as a part of combi-
nation therapy. A total of 284 episodes of bacteremia from 269 patients were
treated with cefepime. Secondary to a lack of MIC data, we excluded 43 episodes,
leaving us with 241 episodes from 229 patients. We further excluded all episodes
of patients who had concomitant bloodstream infection from a gram-positive
organism or fungus. This left us with 204 analyzable episodes of gram-negative
bacteremia from 197 patients.
Microbiologic analysis. Susceptibility testing by broth microdilution (Trek
Diagnostics, OH) was performed on a routine clinical basis by the hospital’s
clinical microbiology laboratory, using CLSI standards (5). Cases in which a
polymicrobial bloodstream infection was present, in which all organisms
were gram-negative bacilli, were classified according to the isolate with the
highest MIC.
Clinical analysis. We collected data including age, sex, presence of immunosup-
pression (neutropenia, history of solid-organ transplant, or AIDS), renal function
(including the need for renal replacement therapy), and the source of bacteremia.
The Acute Physiology and Chronic Health Evaluation (APACHE)-II score (6) was
used to adjust for the severity of illness. The APACHE-II scores were stratified into
quartiles in a manner that has been previously used in the literature (2).
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Definitions. Gram-negative bacteremia was defined as the presence of any
aerobic gram-negative isolate in at least one blood culture. Cases were defined as
discrete episodes of gram-negative bacteremia that were separated by at least 30
days. Polymicrobial infections were defined as those that consisted of two or
more gram-negative isolates. Thus, the a priori primary endpoint was death from
any cause by 28 days after the cefepime therapy was begun (2).
Cefepime dosages. The recommended dosages at the institution were 1 to 2 g
given intravenously every 12 h, for patients with creatinine clearance of 50
ml/min; 1 to 2 g every 24 h, for creatinine clearance of 29 to 50 ml/min; 0.5 to 1 g
every 24 h, for creatinine clearance of 10 to 29 ml/min; 250 to 500 mg every 24 h,
for creatinine clearance of less than 10 ml/min; and 500 mg every 24 h, for
patients on dialysis.
Statistical analysis. Analyses of each individual clinical outcome measure
included only those cases in which a definitive endpoint could be identified. All
variables were examined using PROC GENMOD (SAS software) in a univariate
logistic regression. Factors that had a P value of less than 0.20 in the univariate
analysis were eligible for entry into a multivariable, stepwise logistic regression
model. Variables with a two-sided P value of 0.05 were considered significant.
The breakpoint in the distribution of cefepime MIC distribution was deter-
mined by classification and regression tree (CART; Salford Systems, San Diego,
CA) analysis, a tool to identify breakpoints within ordinal and continuous vari-
ables where the outcome of interest is distinctly different between the resulting
groups. Specifically, CART was used to identify the breakpoint in the cefepime
MIC distribution that maximized the difference in 28-day mortality, thereby
dividing the study population into two groups: those with a high likelihood of
28-day mortality and those with a low likelihood of 28-day mortality. Pruning and
10-fold cross-validation were used in the CART analysis to select the optimal
nested subtree with the smallest misclassification cost.
RESULTS
Analysis was performed with 197 patients with gram-nega-
tive bacteremia who were treated with cefepime. Seven pa-
tients had two episodes of bacteremia so that 204 episodes
were analyzed in total. Patients treated with cefepime were
infected predominantly with P. aeruginosa (n  50), Esche-
richia coli (n  40), Klebsiella pneumoniae (n  26), Serratia
marcescens (n  24), and Enterobacter cloacae (n  21). Ad-
ditionally, there were 24 cases of bacteremia caused by other
gram-negative organisms and 19 cases of polymicrobial gram-
negative organism infections (Table 1). The isolates were
found to have the following MIC breakdown: 115 isolates with
a MIC of 0.25, 11 with a MIC of 0.5, 14 with a MIC of 1, 19
with a MIC of 2, 11 with a MIC of 4, 17 with a MIC of 8, and
17 with a MIC of 16. The greatest number of isolates with a
MIC against cefepime of1 were Escherichia coli (39 isolates),
Klebsiella species (30 isolates), Serratia species (23 isolates),
and Enterobacter species (19 isolates). Pseudomonas aeruginosa
was evenly distributed across the entire MIC spectrum (Ta-
ble 1).
Clinical outcome by cefepime MIC: cefepime-treated pa-
tients. Twenty-one patients were discharged from the hospital
within 28 days of culture-confirmed bloodstream infection and
had no further contact with our hospital’s health care system.
We therefore could not analyze their outcomes at 28 days. The
28-day mortality rate for the remaining 176 patients with gram-
negative bacteremia treated with cefepime was 29.5% (52/176).
The rate of mortality varied by the cefepime MIC of the patho-
gen (Fig. 1); that is, the rate of mortality was 23.3% (27/116
died) for cefepime with a MIC of 1 g/ml, 27.8% (5/18 died)
with a MIC of 2 g/ml, 27.3% (3/11 died) with a MIC of 4
g/ml, 56.3% (9/16 died) with a MIC of 8, and 53.3% (8/15
died) with a MIC of 16 g/ml.
The cefepime MIC breakpoint derived by CART analysis to
delineate the risk of 28-day mortality was 8 g/ml. Patients
with cefepime MICs of 8 g/ml had a twofold or greater
increase in 28-day mortality over that of patients with MICs of
8 g/ml (54.8% and 24.1%, respectively; P  0.001). The
28-day mortality rates were similar for all groups with a MIC of
8 g/ml, and higher 28-day mortality rates were observed
when the cefepime MIC was 8 g/ml (P  0.001, using
linear-by-linear association).
TABLE 1. Distribution and cefepime MICs of 204 bloodstream isolates from cefepime-treated patients
MIC (g/ml)
No. of isolates of:
TotalAcinetobacter
spp. E. coli
Enterobacter
spp.
Klebsiella
spp.
Serratia
spp. P. aeruginosa Miscellaneous
a Polymicrobialb
1 39 19 30 23 7 9 13 140
2 1 1 1 1 12 3 19
4 2 1 7 1 11
8 1 1 1 13 1 17
16 2 3 11 1 17
Total 4 40 26 32 24 50 9 19 204
a Miscellaneous comprises Citrobacter, Providencia, and Pantoea spp. (one isolate from each with a MIC of 1 g/ml), and Proteus spp. (six isolates, all with a MIC
of 1 g/ml).
b For polymicrobial infections, the highest cefepime MIC is recorded.
FIG. 1. Twenty-eight day mortality stratified by cefepime MIC.
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Other predictors of clinical outcome: univariate analysis.
Rising scores of severity of illness were highly correlated with
28-day mortality, as were renal impairment and the need for
renal replacement therapy (Table 2). Specifically, those pa-
tients with an APACHE-II score of 3 to 19 had a mortality rate
of 14.1%, whereas those with a score of 25 to 29 had a mor-
tality rate of 54.5%, and those with a score of 30 to 53 had a
rate of 75% (P values compared to 3 to 19 of 0.0002 and
0.0001, respectively). Patients who were receiving continuous
renal replacement therapy had a mortality rate of 66.7% com-
pared to 14.3% of those with a creatinine clearance of 100
ml/min (P  0.0007). The univariate analysis of 28-day mor-
tality in relation to the organism type showed that patients with
bacteremia caused by P. aeruginosa infection had a trend to-
ward an increased risk of dying (Table 2). There was no rela-
tionship between the organism type and the need for renal
replacement therapy (data not shown). Neither age nor status
of immune system was shown to be a predictor of death.
In order to determine the effect on mortality at 28 days of
the use of combinations of antibiotics active against gram-
negative bacilli plus cefepime, a comparison was made with
monotherapy. A total of 73 patients received monotherapy
with cefepime, and 102 received a combination therapy (Table
2). We found a 30.4% mortality rate with the combination
therapy and a 28.8% rate with cefepime monotherapy (P value,
0.82; odds ratio[OR], 1.08; 95% confidence interval [CI], 0.56
to 2.09).
Predictors of adverse clinical outcome: multivariable anal-
ysis. In our multivariable model of predictors of 28-day mor-
tality, we included all items that had a P value of 0.2 on the
univariate analysis. This consisted of having an APACHE-II
score of 25, a creatinine clearance of 60 ml/min, the use of
continuous renal replacement therapy, a cefepime MIC of 8
g/ml, a central venous line as the source of bacteremia, and
an infection with Pseudomonas aeruginosa. We found that the
use of cefepime against an isolate with a MIC of 8 g/ml
remained an independent risk factor for 28-day mortality (P 
0.001; adjusted OR, 8.2; 95% CI, 2.8 to 24.2). Other indepen-
dent predictors of 28-day mortality on multivariable analysis
included an APACHE-II score of 25 (P  0.0001; OR, 5.9;
95% CI, 2.4 to 14.5), a creatinine clearance rate of 60 ml/
min, and the use of continuous renal replacement therapy (P
0.009; OR, 4.2; 95% CI, 1.4 to 11.4).
In a secondary analysis, patients with cefepime MICs of 8
and 16 g/ml were included at model entry as distinct vari-
ables. Both cefepime MICs of 8 g/ml (P  0.002; adjusted
OR, 9.1; 95% CI, 2.2 to 37.5) and 16 g/ml (P  0.004;
adjusted OR, 7.5; 95% CI, 1.9 to 29.2) were independently
associated with 28-day mortality when scores were adjusted for
the other aforementioned univariate predictor variables.
Outcomes of patients infected with P. aeruginosa. Twenty-
eight-day outcome data were available for 46 patients infected
with P. aeruginosa as the sole bloodstream isolate. Mortality
was higher from P. aeruginosa bacteremia treated with
cefepime when isolates had a cefepime MIC of 8 g/ml
(66.7%; 8/12 died) than when isolates had a cefepime MIC of
4 g/ml (20.8%; 5/24 died) (P 0.01; OR 7.6; 95% CI, 1.7
to 34.5) and higher when the mortality rate for those with a
cefepime MIC of 8 g/ml (59.1%; 13/22 died) was compared
to that of a cefepime MIC of 4 g/ml (20.8%; 5/24 died)
(P  0.008). Specifically, the 28-day mortality rate for patients
with bacteremia due to P. aeruginosa infection was 33% (2/6
died) with a cefepime MIC of 1 g/ml, 18% (2/11 died) with
a cefepime MIC of 2 g/ml, 14% (1/7 died) with a cefepime
MIC of 4 g/ml, 67% (8/12 died) with a cefepime MIC of 8
g/ml, and 50% (5/10 died) with a cefepime MIC of 16
g/ml. There were no differences between the proportion of
patients with P. aeruginosa infection who received combination
TABLE 2. Relationship between predictors of outcome and
mortality at 28 days
Patient dataa
No. of patient
deaths/total
n (%)
P value OR 95% CI
Organism types
E. coli 7/33 (21.2) 0.25b 0.6 0.2–1.5
P. aeruginosa 18/46 (39.1) 0.10 1.8 0.9–3.7
Enterobacter spp. 5/23 (21.7) 0.38 0.6 0.2–1.8
Klebsiella spp. 7/23 (30.4) 0.92 1.05 0.4–2.7
Proteus spp. 1/4 (25) 0.84 0.8 0.08–7.8
Serratia spp. 5/21 (23.8) 0.54 0.7 0.3–2.1
All others 2/7 (28.6) 0.95 0.95 0.2–5.1
Polymicrobial 7/19 (36.8) 0.46 1.5 0.6–3.9
APACHE-II scores
3–19 12/85 (14.1)
20–24 10/38 (26.3) 0.11c 2.2 0.8–5.6
25–29 12/22 (54.5) 0.0002 2.7 1.6–4.5
30–53 12/16 (75) 0.0001 2.6 1.7–4.0
Sources of
bacteremia
CVC 1/14 (7.1) 0.09d 0.2 0.02–1.3
UTI 5/26 (19.2) 0.22 0.5 0.2–1.5
Pneumonia 13/34 (38.2) 0.22 1.6 0.8–3.6
Other 2/9 (22.2) 0.62 0.7 0.1–3.3
Unknown 31/93 (33.3) 0.24 1.5 0.8–2.8
Creatinine clearance
rates
100 ml/min 4/28 (14.3)
60–100 ml/min 7/41 (17.1) 0.76e 1.2 0.3–4.7
60 ml/min 21/57 (36.8) 0.039 3.5 1.1–11.5
CVVHD 12/18 (66.7) 0.0007 12.0 2.8–50.8
HD 7/30 (23.3) 0.28 2.1 0.6–7.9
Immune status
Competent 16/60 (26.7)
Compromised 36/116 (31) 0.55f 1.2 0.6–2.5
Ages
64 28/105 (26.7)
65 24/71 (33.8) 0.31g 1.4 0.7–2.7
Modes of therapy
Monotherapy 21/73 (28.8)
Combination
therapy
31/102 (30.4) 0.82h 1.08 0.56–2.09
a Abbreviations: CVC, central venous catheter; UTI, urinary tract infection;
CVVHD, continuous venovenous hemodialysis; HD, hemodialysis.
b P value compared to that of all other organisms.
c P value compared to that of score range 3–19.
d P value compared to that of all other sources.
e P value compared to that of creatinine clearance of 100 ml/min.
f P value compared to competent status.
g P value compared to those aged 64.
h P value compared to that of monotherapy.
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therapy (52%; 26/50 died) and that of patients infected with
other bacteria (61%; 93/153 died; P  0.32).
Outcomes of patients with beta-lactamase-producing Entero-
bacteriaceae infection. Ten patients infected with organisms
known to be capable of hyperproducing AmpC (e.g., Enterobacter
and Serratia spp., etc.) died within 28 days of developing bacter-
emia. These patients had cefepime MICs of 0.25 g/ml (nine
patients) and 4 g/ml (one patient). (One additional patient who
died had a mixed infection with Enterobacter cloacae [a cefepime
MIC of 8 g/ml] and Pseudomonas aeruginosa [a cefepime MIC
of 1 g/ml]). Only one patient was infected at baseline with an
organism which was resistant to ceftazidime; 0/9 patients with
baseline ceftazidime MICs in the susceptible range had a docu-
mented selection of a mutant isolate resistant to ceftazidime.
Eleven patients were infected with extended-spectrum be-
ta-lactamase (ESBL)-producing organisms (seven patients
were infected with E. cloacae, one with Klebsiella oxytoca,
one with Enterobacter aerogenes, and one with E. coli). A
total of 5 of 10 (50%) patients for whom 28-day mortality
was known died within 28 days of developing bacteremia.
The cefepime MICs of the infecting organisms and patient
outcomes were as follows: 2/3 died (MIC of 2 g/ml), 2/3
died (MIC of 4 g/ml), 1/2 died (MIC of 8 g/ml), and 0/2
died (MIC of 16 g/ml).
Outcomes of patients with regard to cefepime dosing. The
dosing schedules given to patients whose infecting isolates had
a MIC of 8 were 500 mg every 12 h (one patient with an
unknown 28-day mortality), 1 g with dialysis (1/1 died), 1 g
every 24 h (3/4 died), 2 g every 24 h (1/1 died), 1 g every 12 h
(0/4 died), 2 g every 12 h (2/4 died), and 2 g every 8 h (2/2 died).
No correlation was observed between dosing schedule and
mortality rate in this group. However, the numbers were too
limited for formal analysis. Finally, there were no significant
differences in dosing regimens between patients with isolates
whose MICs were less than 8, equal to 8, or greater than 16
(data not shown).
Outcome of patients with gram-negative bacteremia treated
with other antibiotics. In order to determine whether blood-
stream infection with an organism with a cefepime MIC of
8 g/ml is in itself a marker for poor clinical outcome, we
compared the outcome of patients treated with cefepime
versus those treated with other antibiotics to which the
bloodstream isolate was susceptible. For this comparison,
we identified 53 bacteremic patients during the period Jan-
uary 2001 to April 2005 whose bacterial isolates showed a
cefepime MIC of 8 and were treated with an antibiotic other
than cefepime. We excluded cases in which the isolate was
resistant to the chosen therapy or in which the isolate had no
susceptibility result for the antibiotic chosen and patients
who had a concomitant bloodstream infection with a gram-
positive isolate or fungus. This left us with 19 cases from the
same number of patients.
This study group consisted of 10 patients who were treated
with either piperacillin or piperacillin-tazobactam (a piperacil-
lin MIC of 4 g/ml in one patient; a MIC of 32 g/ml in seven
patients; a MIC of 64 g/ml in one patient; and one with no
MIC but a disk diffusion result of susceptible), 3 who were
treated with a quinolone (a ciprofloxacin MIC of 0.25 g/ml in
one patient; a levofloxacin MIC of 0.5 g/ml in one patient;
and a MIC of 1 g/ml in one patient), 4 who were treated with
an aminoglycoside (a tobramycin MIC of 1 g/ml in two
patients, an amikacin MIC of 16 g/ml in one patient, and one
with no MIC but a susceptible disk diffusion result), and 2 who
were treated with a carbapenem (both with a MIC of 2 g/ml).
There were no significant differences between the population
treated with cefepime and the population treated with another
agent, in terms of organism type, APACHE-II scores, sources
of bacteremia, creatinine clearance rates, immune status, age,
or receipt of monotherapy versus combination therapy. The
28-day mortality rate was higher in those treated with cefepime
(56.3%) than those treated with alternative antibiotics (38.9%),
although this difference was not statistically significant (P  0.31;
OR, 2.0; 95% CI, 0.5 to 7.9).
DISCUSSION
Antibiotic susceptibility breakpoints are determined typi-
cally by the integration of a variety of microbiologic, pharma-
cokinetic/pharmacodynamic (PK/PD), and clinical data (4). In
the optimal situation, each of these data components show
consistent results and strongly support a particular breakpoint.
However, it is potentially naı¨ve to think that such a situation
will always occur or that all pieces of data will be both robust
and consistent. This is particularly so when breakpoints are
reconsidered after a particular antibiotic has been in clinical
use for some years. In such a situation, new resistance mech-
anisms may have arisen, causing a “spread” of MICs away from
wild-type distributions. Randomized clinical trials are difficult
to perform after a drug has undergone requirements for reg-
istration as an approved drug. We believe that an examination
of PK/PD and clinical data supports an alteration of the break-
points for cefepime and gram-negative bacilli or a reexamina-
tion of dosing regimens of the drug, even though such data do
not come from recently performed randomized trials.
Since the commercial release of cefepime, new mechanisms
of antibiotic resistance have been detected. These include the
production of ESBLs and metalloenzymes, many of which do
hydrolyze cefepime (7, 11). While some of these organisms
may have very high cefepime MICs (for example, more than 32
g/ml), numerous examples now exist whereby such beta-lac-
tamase-producing organisms have elevated cefepime MICs
compared to that of wild-type organisms, yet the MICs are still
in the susceptible range (“hidden resistance”) (3, 8, 9). The
CLSI currently recommends that ESBL-producing organ-
isms be reported as resistant to cefepime. Small case series
have suggested that the outcome for cefepime-treated pa-
tients is poor for serious infections with ESBL-producing
organisms regardless of the MIC (10). In this study, we have
too small a number to address this question specifically for
ESBL producers, although mortality was substantial (50%
[5/10] died).
Several studies have now assessed the PK/PD profile of
cefepime and would support a change in cefepime breakpoints
or an elimination of all but a dosage regimen of 2 g every 8 h
for empirical therapy of serious infections. A 10,000-subject
Monte Carlo simulation using published mean pharmacoki-
netic parameter estimates and PK/PD targets derived from a
murine infection model has been presented (1). The FDA has
not given a specific label for the use of cefepime in the treat-
ment of bloodstream infections. However, for moderate to
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severe pneumonia due to P. aeruginosa, K. pneumoniae or
Enterobacter spp. infection, the recommended dosage is 1 to
2 g every 12 h; the empirical therapy for febrile, neutropenic
patients is 2 g every 8 h. According to the model just described
(1), the dosage regimen of 1 g of cefepime every 12 h has just
a 35.9% probability of resulting in a percentage of time above
a MIC of greater than 50% if the MIC is 8 g/ml. Thus, these
models would predict that a dose of 1 g every 12 h would most
likely fail if the cefepime MIC is 8 g/ml. However, this par-
ticular model would predict that a dosage regimen of 2 g every
12 h or 2 g every 8 h would have a greater than 90% probability
of resulting in a percentage of time above a MIC of greater
than 50% if the MIC is 8 g/ml. In contrast, an alternative
model showed a probability of the percentage of time above
50% if the MIC was 8 g/ml of 2% for cefepime at 1 g every
12 h, 21% for 2 g every 12 h, and 88% for 2 g every 8 h (10).
It would appear that the preponderance of evidence from
PK/PD analyses suggests that the breakpoint of 8 g/ml is too
high for dosages of cefepime of 1 g every 12 h and quite
possibly also for 2 g every 12 h.
From a clinical perspective, we have evaluated the outcome
of almost 200 patients who received cefepime empirically for
the treatment of gram-negative bacteremia. We found that the
28-day mortality of patients whose organisms had a MIC of 8
g/ml (56.3%) approximated that of patients with MICs out-
side of the susceptible range (53.3%) and far exceeded that of
patients whose organisms had a MIC of8 g/ml (24.1%). We
chose 28-day mortality a priori as our endpoint since this was
the definition in a large trial of patients with sepsis published
in the New England Journal of Medicine (2). In order to account
for important variables such as severity of illness, which may
potentially confound this result, we used a multivariable anal-
ysis. This analysis showed that having a cefepime MIC of 8
g/ml was an independent predictor of 28-day mortality in
patients treated with cefepime for gram-negative bacteremia.
Although 28-day mortality is widely used in other studies, a
particular criticism of this endpoint is that variables other than
antibiotic use may be responsible for the patient’s death. In
order to add another layer of rigor to our analysis, we com-
pared outcomes of patients with bacteremia with cefepime
MICs of 8 g/ml treated with cefepime to those of patients
treated with other antibiotics to which the organism was sus-
ceptible. This was done in order to exclude the hypothesis that
some unforeseen variable leads to inferior outcomes for pa-
tients with bacteremia due to cefepime MICs of 8 g/ml. If that
hypothesis were correct, patients with bacteremia caused by an
organism with a cefepime MIC of 8 g/ml would have poor
outcomes regardless of which antibiotic was chosen. In con-
trast, we found that patients infected with organisms at this
MIC that were treated with alternative antibiotics had a trend
toward superior outcomes compared to those treated with
cefepime, suggesting that this potential hypothesis was in-
correct.
Despite our rigorous clinical analysis of retrospective data,
we would have preferred to have performed a prospective trial
in which patients suspected of having gram-negative bacter-
emia were randomized to cefepime and an alternative antibi-
otic. Ideally, such a trial would include a pharmacokinetic
analysis to determine if suboptimal cefepime “exposure” could
be correlated with suboptimal clinical outcome. Unfortunately,
the sample size of many hundreds of patients required to enroll
sufficient patients with confirmed gram-negative bacteremia
with organisms with a cefepime MIC of 8 g/ml precludes the
initiation of such a study. We are performing a more limited
prospective, pharmacokinetic analysis of patients with serious
gram-negative infections treated with cefepime.
In summary, our data add to the weight of data supporting
a change of breakpoint for cefepime in countries where the
cefepime dosage regimen of 1 to 2 g every 12 h is the licensed
therapy for serious infections. First, two different PK/PD mod-
els strongly show that a cefepime dose of 1 g every 12 h has a
low probability of reaching important PK/PD targets when the
cefepime MIC is 8 g/ml. It could be argued that higher doses
are frequently used, but (i) some models question even the
utility of 2 g every 12 h in treating organisms with a MIC of 8
g/ml, and (ii) there are practical concerns about the commu-
nication of “dose-specific” breakpoints to prescribers. Second,
our clinical data show that 28-day mortality, a widely used
outcome measure in studies of sepsis, is higher in cefepime-
treated patients with gram-negative bacteremia due to organ-
isms with a cefepime MIC of 8 g/ml than in patients infected
with organisms with lower cefepime MICs. While inadequacies
in this clinical study, such as its limited sample size and arbi-
trary outcome measures, are present, we believe the weight of
data does support lowering the cefepime breakpoints so that a
cefepime MIC of 8 g/ml is no longer regarded as susceptible
(if 1 to 2 g every 12 h is a licensed dosing regimen for serious
infections, such as it is in the United States). We would propose
that clinical data of the treatment of serious gram-negative infec-
tions with other antibiotics (for example, piperacillin-tazobactam)
should also be investigated to determine if the breakpoints or
dosing regimens of other commonly used antibiotics should also
be changed.
ACKNOWLEDGMENTS
D.P. received research support from Elan and AstraZeneca and is a
consultant to Merck and Acureon. B.C. and B.P. are on the speakers’
bureau for Wyeth.
REFERENCES
1. Ambrose, P. G., S. M. Bhavnani, R. N. Jones, W. A. Craig, and M. N. Dudley.
2004. Use of pharmacokinetic-pharmacodynamic and Monte-Carlo simula-
tion as decision support for the reevaluation of NCCLS cephem susceptibil-
ity breakpoints for Enterobacteriaceae. Abstr. 44th Intersci. Conf. Antimi-
crob. Agents Chemother., abstr. A-138.
2. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. LaRosa, J. F. Dhainaut, A.
Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W.
Ely, and C. J. Fisher, Jr., for the Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) study group. 2001.
Efficacy and safety of recombinant human activated protein C for severe
sepsis. N. Engl. J. Med. 344:699–709.
3. Bratu, S., D. Landman, R. Haag, R. Recco, A. Eramo, M. Alam, and J.
Quale. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae
in New York City: a new threat to our antibiotic armamentarium. Arch.
Intern. Med. 165:1430–1435.
4. Clinical and Laboratory Standards Institute/NCCLS. 2001. Development of
in vitro susceptibility testing criteria and quality control parameters. Ap-
proved guideline, 2nd ed. Clinical and Laboratory Standards Institute,
Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2006. Performance standards
for antimicrobial susceptibility testing; 16th informational supplement
M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Knaus, W. A., D. P. Wagner, E. A. Draper, J. E. Zimmerman, M. Bergner,
P. G. Bastos, C. A. Sirio, D. J. Murphy, T. Lotring, A. Damiano, et al. 1991.
The APACHE III prognostic system. Risk prediction of hospital mortality
for critically ill hospitalized adults. Chest 100:1619–1636.
7. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum beta-lacta-
mases: a clinical update. Clin. Microbiol. Rev. 18:657–686.
4394 BHAT ET AL. ANTIMICROB. AGENTS CHEMOTHER.
8. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu,
K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu.
2001. Outcome of cephalosporin treatment for serious infections due to
apparently susceptible organisms producing extended-spectrum beta-lacta-
mases: implications for the clinical microbiology laboratory. J. Clin. Micro-
biol. 39:2206–2212.
9. Peleg, A. Y., C. Franklin, J. M. Bell, and D. W. Spelman. 2005. Dissem-
ination of the metallo-beta-lactamase gene blaIMP-4 among gram-nega-
tive pathogens in a clinical setting in Australia. Clin. Infect. Dis. 41:1549–
1556.
10. Reese, A. M., C. R. Frei, and D. S. Burgess. 2005. Pharmacodynamics of
intermittent and continuous infusion piperacillin/tazobactam and cefepime
against extended-spectrum beta-lactamase-producing organisms. Int. J. An-
timicrob. Agents 26:114–119.
11. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-beta-
lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306–325.
VOL. 51, 2007 CEFEPIME BREAKPOINTS 4395
